Procyon looks to milestones with new funding:
This article was originally published in Clinica
Executive Summary
Canadian biotechnology company Procyon Biopharma has raised Can$10 million (US$6.5 million) through further public and private offerings. The Montreal-based company's products include the prognostic and diagnostic applications of prostate secretory protein (PSP94) and COLOPATH, a noninvasive screening test for colorectal cancer licensed to IMI.